Answers are grounded in this paper and cite their sources.
In October 2022, our multicentered institution shifted from using alteplase to tenecteplase for the thrombolytic treatment of acute ischemic stroke (AIS). We aim to report and compare the incidence of hemorrhagic transformation and symptomatic intracranial hemorrhage (sICH) in patients treated with alteplase and tenecteplase at our institution.
No takes yet. Share an insight, caveat, or question.
Caicedo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: